Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Rhythm ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Shares of Sagimet Biosciences soared nearly 40% on Monday, reaching levels not seen since March 2024, as retail sentiment ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a ...

Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.

Explore Summit Therapeutics' stock performance and financial health amid ivonescimab concerns, and learn how to strategically ...